TEVA(US:TEVA) ZACKSยท2025-07-30 14:36Core Insights - Teva Pharmaceutical Industries Ltd. reported revenue of $4.18 billion for the quarter ended June 2025, reflecting a year-over-year increase of 0.3% but a revenue surprise of -2.47% compared to the Zacks Consensus Estimate of $4.28 billion [1] - The earnings per share (EPS) for the quarter was $0.66, surpassing the consensus estimate of $0.63, resulting in an EPS surprise of +4.76% [1] Financial Performance Metrics - Teva's stock has returned -0.6% over the past month, while the Zacks S&P 500 composite has increased by +3.4% [3] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3] Geographic Revenue Breakdown - Revenue from Europe was $1.3 billion, exceeding the average estimate of $1.25 billion, with a year-over-year change of +7% [4] - Revenue from International Markets was $495 million, below the average estimate of $602.4 million, representing a year-over-year decline of -16.5% [4] - Revenue from the United States was $2.15 billion, slightly below the estimated $2.19 billion, with a year-over-year increase of +1.9% [4] - Revenue from Anda in the United States was $365 million, surpassing the average estimate of $358.28 million, but showing a year-over-year decline of -2.1% [4] - Revenue from COPAXONE in Europe was $50 million, exceeding the average estimate of $40.5 million, with a year-over-year decline of -5.7% [4] - Revenue from respiratory products in Europe was $55 million, in line with the estimate of $55.07 million, reflecting a year-over-year decrease of -3.5% [4] - Revenue from generic products in International Markets was $410 million, below the average estimate of $478.57 million, with a year-over-year decline of -15.6% [4] - Revenue from COPAXONE in International Markets was $7 million, significantly below the estimate of $10.83 million, representing a year-over-year decline of -50% [4] - Revenue from AJOVY in the United States was $63 million, exceeding the average estimate of $50.8 million, with a year-over-year increase of +50% [4] - Total revenue from COPAXONE was $119 million, above the average estimate of $101.85 million, but showing a year-over-year decline of -19.6% [4] - Total revenue from other sources was $232 million, below the average estimate of $259.03 million, with a year-over-year increase of +118.9% [4] - API sales to third parties amounted to $135 million, below the average estimate of $156.49 million, with a year-over-year decline of -10.6% [4]